Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 4.7% – What’s Next?

Shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) dropped 4.7% during mid-day trading on Thursday . The stock traded as low as $0.2695 and last traded at $0.2979. 1,613,029 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 5,891,854 shares. The stock had previously closed at $0.3127.

Kairos Pharma Stock Down 4.7%

The company has a market capitalization of $6.38 million, a PE ratio of -0.99 and a beta of 1.50. The stock has a 50-day moving average of $0.42 and a 200 day moving average of $0.56.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter. Equities analysts forecast that Kairos Pharma, Ltd. will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Kairos Pharma

A hedge fund recently raised its stake in Kairos Pharma stock. XTX Topco Ltd boosted its stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) by 290.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,494 shares of the company’s stock after buying an additional 36,086 shares during the quarter. XTX Topco Ltd owned approximately 0.23% of Kairos Pharma worth $34,000 as of its most recent SEC filing.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.